J F Donohue

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi Minimal clinically important differences in COPD lung function
    James F Donohue
    Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, CB 7020, 4125 Bioinformatics Building, Chapel Hill, North Carolina 27599 7020, USA
    COPD 2:111-24. 2005
  2. ncbi New combination therapies for asthma
    J F Donohue
    Pulmonary Division, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7020, USA
    Curr Opin Pulm Med 7:62-8. 2001
  3. ncbi Evaluation of the efficacy and safety of levalbuterol in subjects with COPD
    James F Donohue
    University of North Carolina School of Medicine at Chapel Hill, USA
    COPD 3:125-32. 2006
  4. ncbi Combination therapy for chronic obstructive pulmonary disease: clinical aspects
    James F Donohue
    Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, 4125 Bioinformatics Building, CB 7020, Chapel Hill, NC 27599 7020, USA
    Proc Am Thorac Soc 2:272-81; discussion 290-1. 2005
  5. ncbi Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease
    James F Donohue
    Department of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, 4125 Bioinformatics Bldg, CB 7020, Chapel Hill, NC 27599 7020, USA
    Proc Am Thorac Soc 1:152-60. 2004
  6. ncbi Safety and efficacy of beta agonists
    James F Donohue
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    Respir Care 53:618-22; discussion 623-4. 2008
  7. ncbi Still looking for answers in COPD
    James F Donohue
    Division of Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Lancet 365:1518-20. 2005
  8. doi Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study
    James F Donohue
    School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7020, USA
    Clin Ther 30:989-1002. 2008
  9. ncbi Therapeutic responses in asthma and COPD. Bronchodilators
    James F Donohue
    Division of Pulmonary Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Chest 126:125S-137S; discussion 159S-161S. 2004
  10. ncbi A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD
    James F Donohue
    Division of Pulmonary Medicine, University of North Carolina, Chapel Hill, 27599 7020, USA
    Treat Respir Med 3:173-81. 2004

Detail Information

Publications32

  1. ncbi Minimal clinically important differences in COPD lung function
    James F Donohue
    Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, CB 7020, 4125 Bioinformatics Building, Chapel Hill, North Carolina 27599 7020, USA
    COPD 2:111-24. 2005
    ..Also distributional/statistical methods may be useful in determining the MCID FEV1...
  2. ncbi New combination therapies for asthma
    J F Donohue
    Pulmonary Division, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7020, USA
    Curr Opin Pulm Med 7:62-8. 2001
    ..Many other combination therapies are presently being tested...
  3. ncbi Evaluation of the efficacy and safety of levalbuterol in subjects with COPD
    James F Donohue
    University of North Carolina School of Medicine at Chapel Hill, USA
    COPD 3:125-32. 2006
    ....
  4. ncbi Combination therapy for chronic obstructive pulmonary disease: clinical aspects
    James F Donohue
    Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, 4125 Bioinformatics Building, CB 7020, Chapel Hill, NC 27599 7020, USA
    Proc Am Thorac Soc 2:272-81; discussion 290-1. 2005
    ..Effects on survival are less clear. Some of the other issues to be resolved are the safety of combination therapy, its pharmacoeconomic impact, and the role of newer agents...
  5. ncbi Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease
    James F Donohue
    Department of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, 4125 Bioinformatics Bldg, CB 7020, Chapel Hill, NC 27599 7020, USA
    Proc Am Thorac Soc 1:152-60. 2004
    ..Some evidence suggests that patients with COPD who respond to corticosteroids have eosinophilic inflammation and other attributes of an asthma phenotype...
  6. ncbi Safety and efficacy of beta agonists
    James F Donohue
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    Respir Care 53:618-22; discussion 623-4. 2008
    ..The effect of the beta receptor genotype on beta agonist response is unclear but could hold promise for proper patient management...
  7. ncbi Still looking for answers in COPD
    James F Donohue
    Division of Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Lancet 365:1518-20. 2005
  8. doi Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study
    James F Donohue
    School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7020, USA
    Clin Ther 30:989-1002. 2008
    ..Moreover, it is not clear how the different dosing regimens affect symptom outcomes and health status in hospitalized patients with asthma or COPD...
  9. ncbi Therapeutic responses in asthma and COPD. Bronchodilators
    James F Donohue
    Division of Pulmonary Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Chest 126:125S-137S; discussion 159S-161S. 2004
    ..The roles of stereoisomers, leukotriene receptor antagonists, and type 4 phosphodiesterase inhibitors in asthma and COPD remain uncertain at this time...
  10. ncbi A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD
    James F Donohue
    Division of Pulmonary Medicine, University of North Carolina, Chapel Hill, 27599 7020, USA
    Treat Respir Med 3:173-81. 2004
    ..This is the first comparison of two combination therapies, fluticasone propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of patients with COPD...
  11. ncbi Tolerance to bronchodilating effects of salmeterol in COPD
    J F Donohue
    University of North Carolina School of Medicine, 130 Mason Farm Road, CB 7020 4125 Bioinformatics Bldg, Chapel Hill, NC 27599, USA
    Respir Med 97:1014-20. 2003
    ..In conclusion, tolerance to pharmacologic bronchodilation occurs with long-acting beta-agonists such as salmeterol and not with inhaled anticholinergics...
  12. pmc Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
    James F Donohue
    Division of Pulmonary Disease and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Int J Chron Obstruct Pulmon Dis 6:35-45. 2011
    ..The impact of these many variables on clinical trial results is explored, with a particular focus on changes in inclusion criteria and patient baseline demographics...
  13. ncbi A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol
    James F Donohue
    Division of Pulmonary Medicine, University of North Carolina, Chapel Hill, NC 27599 7020, USA
    Chest 122:47-55. 2002
    ..A trial was designed to examine the efficacy and safety of both compounds with multiple outcome measures, including lung function, dyspnea, and health-related quality of life (HRQoL) in patients with COPD...
  14. doi Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD
    J F Donohue
    Department of Medicine, 111 Mason Farm Road, University of North Carolina College of Medicine, Chapel Hill, NC 27599, USA Electronic address
    Respir Med 107:1538-46. 2013
    ....
  15. ncbi Role of bronchodilators in chronic obstructive pulmonary disease
    Max M Weder
    Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    Semin Respir Crit Care Med 26:221-34. 2005
    ..None of the bronchodilators have been shown to change outcome in COPD, but this issue is under active investigation...
  16. doi Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance
    J F Donohue
    University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Ther Adv Respir Dis 2:37-48. 2008
    ..The study also examined the occurrence of tolerance with these agents, i.e. whether improvement in airway function diminished or frequency of exacerbations increased with 12-months of use...
  17. doi Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, 27599, USA
    Ther Adv Respir Dis 2:199-208. 2008
    ..Most of the FFIS-treated subjects (86%) completed at least six months of open-label treatment with over 90% compliance, comparable to the FA group (88%)...
  18. doi Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
    Am J Respir Crit Care Med 182:155-62. 2010
    ..Indacaterol is the first once-daily, long-acting inhaled beta(2)-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD)...
  19. ncbi Long-acting beta-agonists role in asthma management
    James F Donohue
    Division of Pulmonary Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA
    J Fam Pract . 2006
    ..The NHLBI/NAEPP guidelines recommend inhaled corticosteroids as the first step in controller therapy, with LABAs as an option if low- to medium-dose inhaled corticosteroids do not adequately control the patient's asthma"...
  20. ncbi Accuracy of float testing for metered-dose inhaler canisters
    Tina Penick Brock
    School of Pharmacy, University of North Carolina Chapel Hill, 27599 7560, USA
    J Am Pharm Assoc (Wash) 42:582-6. 2002
    ..To characterize and evaluate canister floating patterns of three commercially available metered-dose inhalers (MDIs) with varying amounts of medication remaining...
  21. ncbi Nontuberculous mycobacteria in women, young and old
    Worakij Chalermskulrat
    Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, 420 Burnett Womack Building, CB 7020, Chapel Hill, NC 27599 7020, USA
    Clin Chest Med 23:675-86. 2002
    ..Studies exclusive to LWS are lacking and are absolutely necessary as they will enhance our understanding of, and hence successful management strategies for, this increasingly recognized disease...
  22. ncbi Ambrisentan for sarcoidosis associated pulmonary hypertension
    M A Judson
    Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, USA
    Sarcoidosis Vasc Diffuse Lung Dis 28:139-45. 2011
    ..Sarcoidosis associated pulmonary hypertension (SAPH) is associated with significant morbidity and mortality. There is a paucity of information concerning therapy for this condition...
  23. ncbi The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life
    Christopher E Cox
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Am J Respir Crit Care Med 168:323-9. 2003
    ..The SHQ alone was sensitive to differences in HRQL based on the number of involved organ systems. In conclusion, we have developed a self-completed HRQL questionnaire for U.S. patients with sarcoidosis...
  24. pmc Tadalafil therapy for sarcoidosis-associated pulmonary hypertension
    H J Ford
    Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
    Pulm Circ 6:557-562. 2016
    ..There was a relatively high dropout rate but no major adverse events and no clinical worsening. Larger studies are needed to explore this question further. (Trial registration: ClinicalTrials.gov identifier: NCT01324999)...
  25. ncbi Health-related quality of life of persons with sarcoidosis
    Christopher E Cox
    Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA
    Chest 125:997-1004. 2004
    ..To describe the health-related quality of life (HRQL) and mental health of persons with sarcoidosis, as well as to assess physician-patient agreement about the presence of sarcoidosis symptoms...
  26. ncbi Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis
    William D Bennett
    Center for Environmental Medicine, Asthma and Lung Biology, University of North Carolina at Chapel Hill, 27599, USA
    Pulm Pharmacol Ther 19:96-100. 2006
    ..17 +/- 10 for salmeterol vs. placebo (P = 0.05 by paired analysis). Thus, in addition to its bronchodilating effects, salmeterol acutely enhances peripheral airway clearance of secretions in mild-moderate chronic bronchitis...
  27. ncbi Ambient air pollution particles and the acute exacerbation of chronic obstructive pulmonary disease
    Thaw Sint
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Inhal Toxicol 20:25-9. 2008
    ..To provide a greater awareness of PM levels, the U.S. Environmental Protection Agency now includes levels of air pollution particles in an air quality index...
  28. ncbi Inhaled corticosteroids and fracture risk: having our cake and eating it too
    Robert Aris
    Chest 127:5-7. 2005
  29. ncbi Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, Texas 77030, USA
    Proc Am Thorac Soc 4:526-34. 2007
    ..Several novel bronchodilators are now in different stages of development for use alone or in combination with other agents...
  30. ncbi The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease
    Stephen I Rennard
    University of Nebraska Medical Center, 985125 Nebraska Medical Center, Omaha, NE 68198, USA
    Am J Respir Crit Care Med 175:926-34. 2007
    ..Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-related, inflammatory lung disease in which tumor necrosis factor-alpha is overexpressed and has been suggested to play a pathogenic role...
  31. ncbi Improved sputum expectoration following a single dose of INS316 in patients with chronic bronchitis
    Fred L Johnson
    Inspire Pharmaceuticals, Inc, 4222 Emperor Boulevard, Suite 470, Durham, NC 27703 8466, USA
    Chest 122:2021-9. 2002
    ....
  32. ncbi Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement
    Robert P Baughman
    University of Cincinnati Medical Center, Cincinnati, OH 45267, USA
    Am J Respir Crit Care Med 174:795-802. 2006
    ..Evidence suggests that tumor necrosis factor (TNF)-alpha plays an important role in the pathophysiology of sarcoidosis...